Eli Lilly and Company (NEO:LLY)

Market Cap	1.16T
Revenue (ttm)	82.77B
Net Income (ttm)	25.65B
Shares Out	n/a
EPS (ttm)	28.47
PE Ratio	45.41
Forward PE	31.06
Dividend	n/a
Ex-Dividend Date	n/a

Volume	161,184
Average Volume	85,814
Open	33.81
Previous Close	34.16
Day's Range	32.89 - 33.90
52-Week Range	22.85 - 34.79
Beta	0.39
RSI	72.21
Earnings Date	Oct 30, 2025

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Cboe Canada
• Ticker Symbol: LLY

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD